Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels
复制标题
DOI：
10.3275/7971
复制
发表时间：
2012-07-01
影响因子：
5.4
通讯作者：
Takasugi, K.
中科院分区：
文献类型：
--
作者：
Mokuda, S.;Okuda, Y.;Takasugi, K.
背景：血清羧化骨钙素（ucOC）是维生素K不足的骨生化标志物。据报道，骨吸收抑制剂倾向于降低原发性骨质疏松患者的血清ucOC水平。在类风湿性关节炎（RA）患者中，这些结果从未报道过。目的：研究绝经后RA患者血清ucOC水平变化的危险因素（no.=100）。对象和方法：20例患者不使用骨吸收抑制剂（对照组），30例患者使用雷洛昔芬（RLX）， 50例患者使用阿仑膦酸钠（ALN）。这项横断面研究仅限于RA疾病活动性低的患者（疾病活动性评分为28分）
Background: Serum undercarboxylated osteocalcin (ucOC) is a biochemical bone marker of vitamin K insufficiency. It had been reported that bone resorption inhibitors tend to decrease the serum ucOC level in patients with primary osteoporosis. In rheumatoid arthritis (RA) patients, these results have never been reported. Aim: We investigated risk factors which could change serum ucOC level in post-menopausal women with RA (no.=100). Subjects and methods: Twenty patients received no bone resorption inhibitor (control), 30 received raloxifene (RLX), while 50 received alendronate (ALN). This cross-sectional study was limited to patients with low RA disease activity (Disease Activity Score-28